GB964989A - Medicines containing a cysteine derivative - Google Patents

Medicines containing a cysteine derivative

Info

Publication number
GB964989A
GB964989A GB27168/61A GB2716861A GB964989A GB 964989 A GB964989 A GB 964989A GB 27168/61 A GB27168/61 A GB 27168/61A GB 2716861 A GB2716861 A GB 2716861A GB 964989 A GB964989 A GB 964989A
Authority
GB
United Kingdom
Prior art keywords
carboxymethylcysteine
hcl
specifications
referred
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB27168/61A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recherches et Propagande Scientifiques
Original Assignee
Recherches et Propagande Scientifiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recherches et Propagande Scientifiques filed Critical Recherches et Propagande Scientifiques
Publication of GB964989A publication Critical patent/GB964989A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

S-Carboxymethylcysteine is prepared by reacting cysteine hydrochloride in aqueous solution containing sodium hydroxide with sodium monochloracetate in an atmosphere of nitrogen, first at 0-5 DEG C. and then at 50 DEG C. at pH 8. After clarification with charcoal, the S-carboxymethylcysteine is precipitated by the addition of HCl to pH 2.8. It is purified by boiling an aqueous suspension containing 25% excess 2N.HCl, cooling to 30 DEG C. and adding 2N.NaOH to pH 2.8. The precipitate is washed free from chloride and air dried. Specifications 797,508 and 825,178 are referred to.ALSO:A therapeutic composition for the treatment of chronic conditions of the respiratory tract comprises a substantially isotonic, aqueous solution containing 1 to 5% by weight of S-carboxymethylcysteine having a pH of 6 to 6.5 and being in a form suitable for administration as nasal drops or as a nasal or pulmonary spray or aerosol. The preferred pH is 6.2 and the preferred concentration of active ingredient is 2%. Optional ingredients are preservatives such as methyl p-hydroxy-benzoate and drugs such as eucalyptol which act locally on the upper respiratory tract. Specifications 797,508 and 825,178 are referred to.
GB27168/61A 1960-08-19 1961-07-26 Medicines containing a cysteine derivative Expired GB964989A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR836305A FR226M (en) 1960-08-19 1960-08-19 Sulfur-containing medicament, usable in particular in otolaryngology and pneumology.

Publications (1)

Publication Number Publication Date
GB964989A true GB964989A (en) 1964-07-29

Family

ID=8737702

Family Applications (1)

Application Number Title Priority Date Filing Date
GB27168/61A Expired GB964989A (en) 1960-08-19 1961-07-26 Medicines containing a cysteine derivative

Country Status (2)

Country Link
FR (1) FR226M (en)
GB (1) GB964989A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857951A (en) * 1973-09-14 1974-12-31 Cassenne Lab Sa Use of 2-mercaptopropionylglycine and its alkali metal salts in treating respiratory diseases
US3891749A (en) * 1969-10-07 1975-06-24 Rech Pharm Scientifiques Digestive pharmaceutical composition comprising S-carboxymethyl cysteine for reducing viscosity of respiratory tract secretions, and method of treating therewith
USRE29256E (en) 1969-10-07 1977-06-07 Recherche Pharmaceutiques Et Scientifiques Digestive pharmaceutical composition comprising S-carboxymethyl cysteine for reducing viscosity of respiratory tract secretions, and method of treating therewith
US5061729A (en) * 1988-06-08 1991-10-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same
CN109745301A (en) * 2017-11-08 2019-05-14 北京盈科瑞创新药物研究有限公司 A kind of carbocisteine Neulized inhalation pharmaceutical solutions and preparation method thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891749A (en) * 1969-10-07 1975-06-24 Rech Pharm Scientifiques Digestive pharmaceutical composition comprising S-carboxymethyl cysteine for reducing viscosity of respiratory tract secretions, and method of treating therewith
USRE29256E (en) 1969-10-07 1977-06-07 Recherche Pharmaceutiques Et Scientifiques Digestive pharmaceutical composition comprising S-carboxymethyl cysteine for reducing viscosity of respiratory tract secretions, and method of treating therewith
US3857951A (en) * 1973-09-14 1974-12-31 Cassenne Lab Sa Use of 2-mercaptopropionylglycine and its alkali metal salts in treating respiratory diseases
US5061729A (en) * 1988-06-08 1991-10-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same
CN109745301A (en) * 2017-11-08 2019-05-14 北京盈科瑞创新药物研究有限公司 A kind of carbocisteine Neulized inhalation pharmaceutical solutions and preparation method thereof
WO2019091082A1 (en) * 2017-11-08 2019-05-16 北京盈科瑞创新药物研究有限公司 Solution preparation for aerosol inhalation of carbocisteine, and preparation method therefor
JP2021502398A (en) * 2017-11-08 2021-01-28 ベイジン インクリース イノベーション ドラッグ リサーチ カンパニー リミテッド Carbocisteine aerosol inhalation solution preparation and its manufacturing method

Also Published As

Publication number Publication date
FR226M (en) 1961-02-27

Similar Documents

Publication Publication Date Title
KR100211479B1 (en) Intranasal formulations of 3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole-5-methanesulphonamide
RU2361593C3 (en) AZELASTINE AND STEROID COMBINATION
GR3005586T3 (en)
IL42764A (en) S-adenosyl-2-methionine tri-p-toluene sulfonate,its preparation and therapeutic compositions containing it
GB964989A (en) Medicines containing a cysteine derivative
GB824908A (en) Improvements in or relating to triazine derivatives
JPS5817167B2 (en) Pharmaceutical composition with antiviral action
ES2052000T3 (en) PROCEDURE FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING PENTAMIDINE.
KR100196060B1 (en) Taurine-based pharmaceutical composition for administration by inhalation
GB939901A (en) Improvements in or relating to amino pyrazoles
JP2003502361A5 (en)
KR900701278A (en) Bile acids for the treatment of viral infections
ES294436A1 (en) Preparation of sodium or potassium salts of polymyxin b and e or colistin formaldehyde-bisulfite reaction products
ATE204474T1 (en) MEDICINAL PRODUCTS CONTAINING AMETHOCAIN
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
KR880003973A (en) Pharmacologically active compounds and uses
US4243679A (en) S-(3-Methyl-2-butenyl)cysteine
SE8701592L (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ORGANIC ZINC COMPLEX AND PROCEDURE FOR PREPARING THE ACTIVE SUBSTANCE
IE34806L (en) Pharmaceutical composition
GB967594A (en) 2-(2,6-dimethyl-3-hydroxy-4-tert-butyl-benzyl)-2-imidazoline,and acid addition salts thereof,and process for their manufacture
EP0486921A1 (en) N-acetyl-L-cysteine magnesium salt and pharmaceutical compositions containing it
US3965167A (en) Crystalline ammonium N-acetyl-L-cysteinate and mucolytic process
JPH02240025A (en) Stable aqueous solution of complex vitamin
DE2960927D1 (en) N1-benzoyl-n2-phenyl-1,3-diaminopropane-2-ols and their salts, process for their preparation and medicaments containing them
GB842325A (en) Pharmaceutical compositions containing aminoguanidine derivatives